Osteoarthritis in 2017

Latest advances in the management of knee OA

Osteoarthritis research in 2017 provided new insights into the long-term effects of intra-articular glucocorticoids, and also led to the approval of a novel, longer-lasting glucocorticoid formulation. New drugs for the treatment of osteoarthritis also emerged this year, including a small-molecule inhibitor of the Wnt signalling pathway.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Research advances in osteoarthritis management.


  1. 1

    Flexion Therapeutics Inc. Zilretta (triamcinolone acetonide extended-release injectable suspension), for intra-articular use [label] Food and Drug Administration https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208845s000lbl.pdf (2017).

  2. 2

    McAlindon, T. E. et al. Effect of intra-articular triamcinolone versus saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 317, 1967–1975 (2017).

    CAS  Article  Google Scholar 

  3. 3

    Yazici, Y. et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage 25, 1598–1606 (2017).

    CAS  Article  Google Scholar 

  4. 4

    McAlindon, T. E. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 22, 363–388 (2014).

    CAS  Article  Google Scholar 

  5. 5

    Bodick, N. et al. An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. J. Bone Joint Surg. Am. 97, 877–888 (2015).

    Article  Google Scholar 

  6. 6

    Conaghan, P. G. et al. Phase 2b trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intra-articular injection in knee osteoarthritis. Arthritis Rheumatol. 10.1002/art.40364 (2017).

  7. 7

    Cicuttini, F. M. et al. Rate of cartilage loss at two years predicts subsequent total knee arthroplasty: a prospective study. Ann. Rheum. Dis. 63, 1124–1127 (2004).

    CAS  Article  Google Scholar 

  8. 8

    Nielsen, F. K., et al. Risk factors for joint replacement in knee osteoarthritis; a 15-year follow-up study. BMC Musculoskelet. Disord. 18, 510 (2017).

    Article  Google Scholar 

  9. 9

    Deshmukh, V. et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 26, 18–27 (2018).

    CAS  Article  Google Scholar 

  10. 10

    Bannuru, R. R. et al. Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials. Ann. Intern. Med. 163, 365–372 (2015).

    Article  Google Scholar 

Download references


The work of T.E.M. is supported by the NIH. The work of R.R.B. is supported by the NIH National Center for Complementary and Integrative Health (NCCIH). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the NCCIH.

Author information



Corresponding author

Correspondence to Timothy E. McAlindon.

Ethics declarations

Competing interests

T.E.M. declares that he has acted as a consultant for Flexion Therapeutics and as an Advisory Board member for Samumed. R.R.B. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

McAlindon, T., Bannuru, R. Latest advances in the management of knee OA. Nat Rev Rheumatol 14, 73–74 (2018). https://doi.org/10.1038/nrrheum.2017.219

Download citation

Further reading